Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Fas Ligand/TNFSF6 Antibody (14C2) - BSA Free, Novus Biologicals™

Mouse Monoclonal Antibody
Supplier: Novus Biologicals NB10063072
Description
Fas Ligand/TNFSF6 Monoclonal specifically detects Fas Ligand/TNFSF6 in Human samples. It is validated for Flow Cytometry, ELISA, Immunoprecipitation, Western Blot (Negative).Specifications
| Fas Ligand/TNFSF6 | |
| Monoclonal | |
| 1.0 mg/mL | |
| Flow Cytometry 1:25 - 1:50, ELISA 1:100 - 1:2000, Immunoprecipitation 1:10 - 1:500, Western Blot (Negative) | |
| apoptosis (APO-1) antigen ligand 1, Apoptosis antigen ligand, APT1LG1CD95L, APTL, CD178, CD178 antigen, CD95-L, Fas antigen ligand, Fas ligand, Fas ligand (TNF superfamily, member 6), FASLCD95 ligand, TNFSF6FasL, tumor necrosis factor (ligand) superfamily, member 6, tumor necrosis factor ligand superfamily member 6 | |
| Mouse | |
| Protein G purified | |
| RUO | |
| Primary | |
| NB100-63072 recognizes the human CD178 cell surface antigen, a 40kDa glycoprotein also known as Fas ligand (CD95L). CD178 is a member of the TNF family, which is expressed by activated T lymphocytes and NK cells. The protein may exist as either a membrane bound or a cleaved soluble form. CD178 plays an important role in T cell development cytotoxicity. Binding of CD178 to Fas (CD95) results in the induction of apoptosis. Clone 14C2 is not reported to have a blocking function. | |
| Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles. | |
| IgG1 |
| Flow Cytometry, ELISA, Immunoprecipitation, Western Blot | |
| 14C2 | |
| Unconjugated | |
| P48023 | |
| FASLG | |
| Made to Human CD178 | |
| 0.1 mg | |
| Apoptosis, Cancer, Diabetes Research | |
| 356 | |
| Human | |
| Purified |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
For Research Use Only
Spot an opportunity for improvement?Share a Content Correction